Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

Exclusion Criteria

• •Orbital decompression surgery needed immediately
• •Active smoker
• •Patients who could need treatment with radioactive iodine or thyroidectomy during the study
• •Pregnant patient or patient who is planning to become pregnant during the study
• •History of chronic recurrent or active infection
• •History of intestinal ulceration or diverticulitis
• •Patients with a history of chronic liver disease or liver disorders: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)
• •History of HIV, hepatitis C or hepatitis B Positive
• •Neutrophil count \< 0.5 × 109/L or a platelet count \< 50×103/μL
• •Simultaneous use or contraindications to the use of immunosuppressive agents
• •A treatment with another investigational drug within four weeks of selection or five half-lives of study drug
• •Cardiovascular or cerebrovascular disease clinically significant
• •Uncontrolled diabetes mellitus
• •Use of corticosteroids during four weeks before to inclusion period
• •History of reactions or anaphylactic allergic severe human monoclonal antibodies, humanized or murine
• •Uncontrolled pathologies, whose exacerbations are treated with corticosteroids